Journal of Medicinal Chemistry · 2024 · 20 citations · 11 references
PharmacyInfectious DiseasesMedicinal ChemistryDrug DiscoveryMolecular VirologyVirologyAntiviral PharmacologyAntiviral TherapyAntiviral TherapeuticsHepatocyte ClearanceSars-cov-2 Antiviral TherapyTreatment Of Coronavirus InfectionsViral Protease FunctionViral Protease InhibitionViral ProteasesViral Therapeutic Targets
High Resolution Image Download MS PowerPoint Slide There remains a need to develop novel SARS-CoV-2 therapeutic options that improve upon existing therapies by an increased robustness of response, fewer safety liabilities, and global-ready accessibility. Functionally critical viral main protease (M pro, 3CL pro ) of SARS-CoV-2 is an attractive target due to its homology within the coronaviral family, and lack thereof toward human proteases. In this disclosure, we outline the advent of a novel SARS-CoV-2 3CL pro inhibitor, CMX990, bearing an unprecedented trifluoromethoxymethyl ketone warhead. Compared with the marketed drug nirmatrelvir (combination with ritonavir = Paxlovid), CMX990 has distinctly differentiated potency (∼5× more potent in primary cells) and human in vitro clearance (>4× better microsomal clearance and >10× better hepatocyte clearance), with good in vitro -to- in vivo correlation. Based on its compelling preclinical profile and projected once or twice a day dosing supporting unboosted oral therapy in humans, CMX990 advanced to a Phase 1 clinical trial as an oral drug candidate for SARS-CoV-2.
11
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
Wenhao Dai, Bing Zhang, Xia-Ming Jiang et al. · Science · 2020 · 1.6K citations · Full text
Linlin Zhang, Daizong Lin, Yuri Kusov et al. · Journal of Medicinal Chemistry · 2020 · 606 citations · Full text
Robert L. Hoffman, Robert S. Kania, Mary A. Brothers et al. · Journal of Medicinal Chemistry · 2020 · 533 citations · Full text